Protein S human

DB13149

biotech approved

Deskripsi

Protein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties A19561. It serves as a negative feedback mechanism in the coagulation cascade.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Interaksi Obat

644 Data
Apixaban Apixaban may increase the anticoagulant activities of Protein S human.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Protein S human.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Protein S human.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Protein S human is combined with Deferasirox.
Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Cholic Acid.
Glycocholic acid The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Taurocholic acid.
Obeticholic acid The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Hyodeoxycholic Acid.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Protein S human.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Protein S human.
Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Protein S human is combined with Obinutuzumab.
Rivaroxaban Protein S human may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Protein S human is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Protein S human.
Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Protein S human.
Urokinase Urokinase may increase the anticoagulant activities of Protein S human.
Vitamin E Vitamin E may increase the anticoagulant activities of Protein S human.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Protein S human.
Ginkgo biloba Ginkgo biloba may increase the anticoagulant activities of Protein S human.
Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Protein S human.
Quinine The therapeutic efficacy of Protein S human can be increased when used in combination with Quinine.
Quinidine The therapeutic efficacy of Protein S human can be increased when used in combination with Quinidine.
Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Protein S human.
Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Protein S human.
Pentoxifylline The therapeutic efficacy of Protein S human can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Protein S human.
Levocarnitine The therapeutic efficacy of Protein S human can be increased when used in combination with Levocarnitine.
Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Protein S human.
Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Protein S human.
Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Protein S human.
Mestranol The risk or severity of adverse effects can be increased when Mestranol is combined with Protein S human.
Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Protein S human.
Quinestrol Quinestrol may decrease the anticoagulant activities of Protein S human.
Hexestrol Hexestrol may decrease the anticoagulant activities of Protein S human.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Protein S human.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Protein S human.
Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Protein S human.
Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Protein S human.
Zeranol Zeranol may decrease the anticoagulant activities of Protein S human.
Equol Equol may decrease the anticoagulant activities of Protein S human.
Methallenestril Methallenestril may decrease the anticoagulant activities of Protein S human.
Epimestrol Epimestrol may decrease the anticoagulant activities of Protein S human.
Moxestrol Moxestrol may decrease the anticoagulant activities of Protein S human.
Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Protein S human.
Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Protein S human.
Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Protein S human.
Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Protein S human.
Biochanin A Biochanin A may decrease the anticoagulant activities of Protein S human.
Formononetin Formononetin may decrease the anticoagulant activities of Protein S human.
Estriol Estriol may decrease the anticoagulant activities of Protein S human.
Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Protein S human.
Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Protein S human.
Mesalazine The risk or severity of bleeding can be increased when Mesalazine is combined with Protein S human.
Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Protein S human.
Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Protein S human.
Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Protein S human.
Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Protein S human.
Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Protein S human.
Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Protein S human.
Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Protein S human.
Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Protein S human.
Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Protein S human.
Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Protein S human.
Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Protein S human.
Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Protein S human.
Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Protein S human.
Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Protein S human.
Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Protein S human.
Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Protein S human.
Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Protein S human.
Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Protein S human.
Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Protein S human.
Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Protein S human.
Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Protein S human.
Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Protein S human.
Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Protein S human.
Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Protein S human.
Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Protein S human.
Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Protein S human.
Olsalazine The risk or severity of bleeding can be increased when Olsalazine is combined with Protein S human.
Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Protein S human.
Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Protein S human.
Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Protein S human.
Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Protein S human.
Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Protein S human.
Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Protein S human.
Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Protein S human.
Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Protein S human.
Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Protein S human.
Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Protein S human.
Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Protein S human.

Target Protein

Coagulation factor V F5
Coagulation factor X F10
Vitamin K-dependent protein C PROC

Referensi & Sumber

Artikel (PubMed)
  • PMID: 15118541
    Rigby AC, Grant MA: Protein S: a conduit between anticoagulation and inflammation. Crit Care Med. 2004 May;32(5 Suppl):S336-41.
  • PMID: 24835672
    Somajo S, Koshiar RL, Norstrom E, Dahlback B: Protein S and factor V in regulation of coagulation on platelet microparticles by activated protein C. Thromb Res. 2014 Jul;134(1):144-52. doi: 10.1016/j.thromres.2014.04.031. Epub 2014 May 2.
  • PMID: 12193728
    Webb JH, Blom AM, Dahlback B: Vitamin K-dependent protein S localizing complement regulator C4b-binding protein to the surface of apoptotic cells. J Immunol. 2002 Sep 1;169(5):2580-6.
  • PMID: 8063724
    Hackeng TM, van 't Veer C, Meijers JC, Bouma BN: Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem. 1994 Aug 19;269(33):21051-8.

Contoh Produk & Brand

Produk: 7 • International brands: 0
Produk
  • Balfaxar
    Powder, for solution • - • Intravenous • US • Approved
  • Beriplex P/n 1000
    Powder, for solution • - • Intravenous • Canada • Approved
  • Beriplex P/n 500
    Powder, for solution • - • Intravenous • Canada • Approved
  • Kcentra
    Injection, powder, lyophilized, for solution; Kit • - • Intravenous • US • Approved
  • Kcentra
    Injection, powder, lyophilized, for solution; Kit • - • Intravenous • US • Approved
  • Octaplex
    Kit; Powder, for solution • - • Intravenous • Canada • Approved
  • Octaplex
    Kit; Powder, for solution • - • Intravenous • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul